Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012
[ Mon, Jul 16th 2012 ] - Market Wire
30 a.m. ET
Fri, July 13, 2012
Thu, July 12, 2012
Wed, July 11, 2012
Tue, July 10, 2012
Mon, July 9, 2012
[ Mon, Jul 09th 2012 ] - Market Wire
Mesa Labs Announces New Logo

Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call


//health-fitness.news-articles.net/content/2012/ .. rter-2012-financial-results-conference-call.html
Published in Health and Fitness on Monday, July 23rd 2012 at 4:20 GMT by Market Wire   Print publication without navigation


Webcast Alert: Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call -- CARLSBAD, Calif., July 23, 2012 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call

[ ]

CARLSBAD, Calif., July 23, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: [ ISIS ]) announces the following webcast:

What:

Isis Pharmaceuticals' Second Quarter 2012 Financial Results Conference Call

When:

Monday, August 6, 2012 at 11:30 a.m. ET / 8:30 a.m. PT

Where:

[ www.isispharm.com ]

How:

Live on the Internet.  Simply log onto our Web site listed above.

Contacts:

Kristina Lemonidis
Director, Investor Relations
(760) 603-2490

Amy Blackley, Ph.D.
Associate Director, Corporate Communications
(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at [ www.isispharm.com ].

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO™, in the United States and Europe following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.



[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources